Recurrent fixed drug eruption caused by citiolone.
M de Barrio, P Tornero, A Prieto, T Sainza, J M Zubeldia, T Herrero
Index: J. Investig. Allergol. Clin. Immunol. 7(3) , 193-4, (1997)
Full Text: HTML
Abstract
Citiolone (N-acetylhomocysteinethiolactone) is a thiolic-derived medication frequently used in Spain and in other countries as a mucolytic agent for the treatment of certain hepatic disorders. Mucolytic drugs have rarely been implicated in the fixed drug eruption etiology. We report on a patient who presented several episodes of fixed exanthema related to citiolone intake. The patch test with citiolone (10% in dimethyl sulfoxide) was negative. The diagnosis was confirmed by a positive controlled oral challenge test. Other mucolytic thiolic-derivatives (N-acetylcysteine) were tolerated by the patient, thus crossreactivity between these drugs seems to be unlikely.
Related Compounds
Related Articles:
Interleukin-1 beta increases the activity of superoxide dismutase in rat pancreatic islets.
1992-05-01
[Endocrinology 130(5) , 2851-7, (1992)]
Inability of thiol compounds to restore CNS arylsulfatases inhibited by methyl mercury.
1991-07-01
[Pharmacol. Toxicol. 69(1) , 71-4, (1991)]
1992-07-01
[Bull. Environ. Contam. Toxicol. 49(1) , 71-7, (1992)]
Fixed drug eruption due to citiolone.
1995-11-01
[Contact Dermatitis 33(5) , 352, (1995)]
Prevention of low dose streptozotocin-induced diabetes by acetyl-homocysteine-thiolactone.
1991-08-01
[Diabetes Res. Clin. Pract. 13(1-2) , 95-102, (1991)]